In the midst of Warsaw, Ind.-based Zimmer Biomet's acquisition of Austin, Texas-based LDR, other spine device companies may be considering future transactions, according to The Street.
Here are five takeaways:
1. Although the spine device market is hindered by costly procedures and pricing restrictions, the Zimmer Biomet-LDR transaction suggests there is opportunity in the space.
2. With its acquisition of LDR, Zimmer Biomet is positioning itself to be a dominant player in the spine device market.
3. This acquisition may, in turn, inspire other deals as companies try to compete.
4. LDR proved an attractive target as it develops the Mobi-C CDR device, which is the only FDA-approved device to treat one- and two-level cervical damaged discs.
5. Zimmer Biomet anticipates completing the $1 billion acquisition in the third quarter of 2016.